Safety of Peripherally Infused Sympathomimetic Vasopressors in the Intensive Care Unit and Emergency Department.

IF 2.3 4区 医学 Q3 PHARMACOLOGY & PHARMACY
Albert Zichichi, Ryan Wallace, Jessica Daniell, Ginger Rouse, Paul Ahearn, Mahmoud Ammar
{"title":"Safety of Peripherally Infused Sympathomimetic Vasopressors in the Intensive Care Unit and Emergency Department.","authors":"Albert Zichichi, Ryan Wallace, Jessica Daniell, Ginger Rouse, Paul Ahearn, Mahmoud Ammar","doi":"10.1177/10600280241284796","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Sympathomimetic vasopressors may be administered through a peripheral catheter, but there are limited data available on the safety of peripheral use.</p><p><strong>Objective: </strong>The purpose of this study was to analyze the safety of peripherally infused sympathomimetic vasopressors.</p><p><strong>Methods: </strong>A multicenter, retrospective observational study was conducted to evaluate patients who received peripheral vasopressors. The study's primary outcome was to assess the incidence of extravasation during the administration of peripheral vasopressors. Secondary outcomes include avoidance of central venous catheter (CVC) placement and institution protocol deviations.</p><p><strong>Results: </strong>There were 198 patients included in the study, of which 142 patients received norepinephrine, 48 patients received phenylephrine, and 8 patients received epinephrine peripherally. Extravasation events occurred in 11 (5.6%) patients. Seven patients required a pharmacologic antidote and 10 patients required a warm compress. No significant differences were seen in characteristics of patients who extravasated compared with those who did not. Protocol deviations identified during the study included 24 (12.1%) patients receiving doses above the protocol maximum, 19 (9.6%) with a body mass index above the protocol maximum, and 45 (22.7%) patients receiving peripheral vasopressor over 24 hours. The majority of patients were able to avoid CVC placement (59.1%).</p><p><strong>Conclusion and relevance: </strong>Peripherally infused sympathomimetic vasopressors are safe to administer up to 24 hours with a low incidence of extravasation events while avoiding CVC placement in the majority of patients.</p>","PeriodicalId":7933,"journal":{"name":"Annals of Pharmacotherapy","volume":" ","pages":"10600280241284796"},"PeriodicalIF":2.3000,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Pharmacotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/10600280241284796","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Sympathomimetic vasopressors may be administered through a peripheral catheter, but there are limited data available on the safety of peripheral use.

Objective: The purpose of this study was to analyze the safety of peripherally infused sympathomimetic vasopressors.

Methods: A multicenter, retrospective observational study was conducted to evaluate patients who received peripheral vasopressors. The study's primary outcome was to assess the incidence of extravasation during the administration of peripheral vasopressors. Secondary outcomes include avoidance of central venous catheter (CVC) placement and institution protocol deviations.

Results: There were 198 patients included in the study, of which 142 patients received norepinephrine, 48 patients received phenylephrine, and 8 patients received epinephrine peripherally. Extravasation events occurred in 11 (5.6%) patients. Seven patients required a pharmacologic antidote and 10 patients required a warm compress. No significant differences were seen in characteristics of patients who extravasated compared with those who did not. Protocol deviations identified during the study included 24 (12.1%) patients receiving doses above the protocol maximum, 19 (9.6%) with a body mass index above the protocol maximum, and 45 (22.7%) patients receiving peripheral vasopressor over 24 hours. The majority of patients were able to avoid CVC placement (59.1%).

Conclusion and relevance: Peripherally infused sympathomimetic vasopressors are safe to administer up to 24 hours with a low incidence of extravasation events while avoiding CVC placement in the majority of patients.

重症监护室和急诊科外周注入拟交感神经血管加压素的安全性。
背景:交感类血管加压药可通过外周导管给药,但有关外周用药安全性的数据有限:交感神经血管加压药可通过外周导管给药,但有关外周给药安全性的数据有限:本研究旨在分析外周输注拟交感神经血管加压药的安全性:这项多中心、回顾性观察研究对接受外周血管加压药的患者进行了评估。研究的主要结果是评估外周血管加压药用药期间外渗的发生率。次要结果包括避免中心静脉导管(CVC)置入和机构协议偏差:共有 198 名患者参与研究,其中 142 名患者接受去甲肾上腺素治疗,48 名患者接受苯肾上腺素治疗,8 名患者接受肾上腺素外周治疗。11名患者(5.6%)发生了外渗事件。7 名患者需要药物解毒,10 名患者需要热敷。与未发生外渗的患者相比,发生外渗的患者特征无明显差异。研究期间发现的规程偏差包括:24 名患者(12.1%)接受的剂量超过规程规定的最大剂量;19 名患者(9.6%)的体重指数超过规程规定的最大值;45 名患者(22.7%)在 24 小时内接受外周血管加压。大多数患者能够避免置入 CVC(59.1%):外周输注拟交感神经血管加压剂可安全使用长达 24 小时,外渗事件发生率较低,同时大多数患者可避免置入 CVC。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.70
自引率
0.00%
发文量
166
审稿时长
3-8 weeks
期刊介绍: Annals of Pharmacotherapy (AOP) is a peer-reviewed journal that advances pharmacotherapy throughout the world by publishing high-quality research and review articles to achieve the most desired health outcomes.The articles provide cutting-edge information about the most efficient, safe and cost-effective pharmacotherapy for the treatment and prevention of various illnesses. This journal is a member of the Committee on Publication Ethics (COPE). Average time from submission to first decision: 14 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信